Chemotherapy for metastatic colorectal cancer after failure of treatment with irinotecan and oxaliplatin
10.3969/j.issn.1000-8179.20131736
- VernacularTitle:奥沙利铂和伊立替康治疗失败后转移性结直肠癌的化疗选择
- Author:
Junbao LIU
;
Yurong ZHANG
;
Tao QU
;
Shuping SHI
;
Zhujun SHAO
;
Tingting YANG
;
Haijian TANG
;
Nan WANG
;
Wei LIU
;
Chunhui GAO
;
Chengxu CUI
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
salvage chemotherapy agent;
oxaliplatin pemetrexed
- From:
Chinese Journal of Clinical Oncology
2013;(23):1464-1467
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This retrospective study aims to determine the efficacy of chemotherapy and improve a salvage chemother-apy agent for metastatic colorectal cancer (MCRC) after failure of treatment with irinotecan and oxaliplatin. Methods:Between Janu-ary 2002 and March 2013, 37 patients with metastatic MCRC who had progressed after treatment with irinotecan and oxaliplatin were analyzed for their response rate (RR) and progression-free survival (PFS). Results:The overall RR of the 37 patients was 13.51%, with 5 cases of partial response (PR), 12 cases of disease stabilization (SD), and 20 cases of progression (PD). Compared with other chemo-therapy regimens, treatment with a pemetrexed-based chemotherapy agent had a higher RR (17.64%vs. 10.00%, P=0.64) without a lon-ger PFS (2.00 months vs. 1.63 months, HR=0.79, 95%, CI:0.35 to 1.78, P=0.58). Compared with other chemotherapy regimens, treat-ment with a raltirexed-based chemotherapy agent had a higher RR (16.67%vs. 12.00%, P=0.34) without a longer PFS (1.58 months vs. 1.90 months, HR=2.24, 95%, CI:0.98 to 5.12, P=0.06).Conclusion:In patients with MCRC after failure of treatment with irinotecan and oxaliplatin, a pemetrexed-based or raltirexed-based chemotherapy agent may beneficial during salvage treatment and is therefore worthy of further study.
